Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
暂无分享,去创建一个
[1] K. Kaushansky,et al. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. , 2010, Blood.
[2] T. Barbui,et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. , 2009, Blood.
[3] S. Verstovsek,et al. JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? , 2006, Leukemia.
[4] W. Vainchenker,et al. primitive myelofibrosis Evidence for MPL W515L/K mutations in hematopoietic stem cells in , 2013 .
[5] M. Cazzola,et al. JAK2 (V617F) mutation in healthy individuals , 2007, British journal of haematology.
[6] L. Rallidis,et al. No evidence of frequent association of the JAK2 V617F mutation with acute myocardial infarction in young patients , 2009, Leukemia.
[7] J. Maciejewski,et al. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation , 2009, Leukemia.
[8] P. Nguyen,et al. Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.
[9] B. Johansson,et al. The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations. , 2010, Human molecular genetics.
[10] Paola Guglielmelli,et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. , 2007, Blood.
[11] D. Steensma,et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained , 2006, Leukemia.
[12] T. Barbui,et al. Thrombosis in primary myelofibrosis: incidence and risk factors. , 2009, Blood.
[13] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[14] R. Levine,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[15] H. Lodish,et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[16] A. Hagemeijer,et al. Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.
[17] Miyuki Abe,et al. STAT5 Activation Is Critical for the Transformation Mediated by Myeloproliferative Disorder-associated JAK2 V617F Mutant* , 2009, The Journal of Biological Chemistry.
[18] A. Porwit,et al. MPLW515L mutation in acute megakaryoblastic leukaemia , 2009, Leukemia.
[19] W. Hiddemann,et al. CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes , 2009, Clinical Cancer Research.
[20] A. Tefferi,et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera , 2007, Leukemia.
[21] D. Birnbaum,et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias , 2010, Leukemia.
[22] A. Tichelli,et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. , 2010, Blood.
[23] P. Guglielmelli,et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal , 2008, Leukemia.
[24] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[25] A. Tefferi,et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera , 2007, Leukemia.
[26] M. Loh,et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. , 2009, Blood.
[27] B. Bellosillo,et al. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis , 2007, Haematologica.
[28] O. Abdel-Wahab,et al. Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms , 2009, American journal of hematology.
[29] J. Soulier,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[30] H. Kantarjian,et al. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis , 2008, Leukemia.
[31] T. Barbui,et al. The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation. , 2007 .
[32] Sandra A. Moore,et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.
[33] P. Guglielmelli,et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. , 2007, British journal of haematology.
[34] W. Vainchenker,et al. Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage , 2009, Leukemia.
[35] Jungwon Huh,et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.
[36] G. Mufti,et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Mesa,et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival , 2008, Leukemia.
[38] D. Gilliland,et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.
[39] N. Yoo,et al. Absence of IDH2 codon 172 mutation in common human cancers , 2009, International journal of cancer.
[40] D. Gilliland,et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.
[41] Jen-Fen Fu,et al. Identification of CBL, a proto‐oncogene at 11q23.3, as a novel MLL fusion partner in a patient with de novo acute myeloid leukemia , 2003, Genes, chromosomes & cancer.
[42] P. Campbell,et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.
[43] S. Mathew,et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23) , 2003, Leukemia.
[44] C. Bloomfield,et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.
[45] M. Björkholm,et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. , 2008, Blood.
[46] C. Pecquet,et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. , 2010, Blood.
[47] D. Linch,et al. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. , 2009, Blood.
[48] J. Gécz,et al. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients , 2008, Leukemia.
[49] D. Gilliland,et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations , 2007, Leukemia.
[50] B. Quesnel,et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis , 2006, Leukemia.
[51] M. Cazzola,et al. The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera , 2009, Leukemia.
[52] K. Inokuchi,et al. Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia , 2008, Leukemia.
[53] A. Kohlmann,et al. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis , 2010, Haematologica.
[54] O. Abdel-Wahab,et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. , 2010, Cancer research.
[55] C. Hoogenraad,et al. Segregation of non‐p.R132H mutations in IDH1 in distinct molecular subtypes of glioma , 2010, Human mutation.
[56] M. Cazzola,et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. , 2008, Blood.
[57] Andrey Korshunov,et al. Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.
[58] P. Fialkow,et al. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. , 1978, Blood.
[59] M. Stratton,et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.
[60] O. Bernard,et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias , 2010, Leukemia.
[61] O. Kilpivaara,et al. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science , 2008, Leukemia.
[62] T. Barbui,et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. , 2008, Blood.
[63] D. Gilliland,et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML , 2009, Leukemia.
[64] T. Haferlach,et al. Detection of Three Different MPLW515 Mutations in 10.1% of All JAK2 V617 Unmutated ET and 9.3% of All JAK2 V617F Unmutated OMF: A Study of 387 Patients. , 2007 .
[65] G. Booz,et al. JAK redux: a second look at the regulation and role of JAKs in the heart. , 2009, American journal of physiology. Heart and circulatory physiology.
[66] J. Issa,et al. JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5 , 2010, Leukemia.
[67] R. Kralovics. Genetic complexity of myeloproliferative neoplasms , 2008, Leukemia.
[68] S. Um,et al. ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1* , 2009, The Journal of Biological Chemistry.
[69] R. Kralovics,et al. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. , 2009, Blood.
[70] P. Kleihues,et al. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.
[71] J. Spivak,et al. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[72] P. Campbell,et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. , 2008, Blood.
[73] A. Tefferi,et al. The complete evaluation of erythrocytosis: congenital and acquired , 2009, Leukemia.
[74] A. Tefferi,et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms , 2010, Leukemia.
[75] A. Tefferi,et al. JAK2 mutations in myeloproliferative disorders. , 2005, The New England journal of medicine.
[76] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[77] Jih-Luh Tang,et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. , 2010, Blood.
[78] W. Vainchenker,et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. , 2008, Blood.
[79] A. Tsygankov,et al. The Cbl family proteins: Ring leaders in regulation of cell signaling , 2006, Journal of cellular physiology.
[80] M. Cazzola,et al. Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations: a European Multicenter Study , 2009 .
[81] Soon-Siong Teo,et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. , 2006, Blood.
[82] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[83] R. Kusec,et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. , 2010, Blood.
[84] D. Birnbaum,et al. Mutations of ASXL1 gene in myeloproliferative neoplasms , 2009, Leukemia.
[85] D. Gilliland,et al. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients , 2008, Leukemia.
[86] A. Tefferi,et al. Conventional cytogenetics in myelofibrosis: literature review and discussion , 2009, European journal of haematology.
[87] J. O’Shea,et al. Janus kinases in immune cell signaling , 2009, Immunological reviews.
[88] T. Barbui,et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden , 2007, Leukemia.
[89] M. Baccarani,et al. JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients , 2009, Leukemia & lymphoma.
[90] P. Campbell,et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. , 2006, Blood.
[91] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[92] Daniel Birnbaum,et al. Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.
[93] J. Duyster,et al. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. , 2009, Blood.
[94] G. Reifenberger,et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] M. Olschewski,et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis , 2008, Haematologica.
[96] P. Jégo,et al. The JAK2V617F mutation may be present several years before the occurrence of overt myeloproliferative disorders , 2008, Leukemia.
[97] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[98] A. Green,et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones , 2009, British journal of haematology.
[99] D. Steensma,et al. The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .
[100] P. Murray. The JAK-STAT Signaling Pathway: Input and Output Integration1 , 2007, The Journal of Immunology.
[101] D. Birnbaum,et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia , 2009, Haematologica.
[102] A. Hall,et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: A model for the basis of unbalanced translocations in cancer , 2008, Proceedings of the National Academy of Sciences.
[103] S. Constantinescu,et al. Aberrant signal transduction pathways in myeloproliferative neoplasms , 2008, Leukemia.
[104] A. Tefferi,et al. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. , 2010, Leukemia.
[105] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[106] B. Fridley,et al. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. , 2008, Blood.
[107] G. Mufti,et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. , 2005, Gastroenterology.
[108] A. Tefferi,et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia , 2007, Cancer.
[109] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[110] S. Fiering,et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. , 2009, Blood.
[111] R. Levine,et al. Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation , 2008, Leukemia.
[112] Andrew J. Bannister,et al. JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin , 2009, Nature.
[113] D. Birnbaum,et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.
[114] M. Wadleigh,et al. The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera , 2006, Cancer.
[115] A. Tefferi. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1 , 2008, Journal of cellular and molecular medicine.
[116] T. Cenci,et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis , 2010, Haematologica.
[117] A. Tefferi,et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival , 2010, Leukemia.
[118] David P Steensma,et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. , 2005, Blood.
[119] M. Cazzola,et al. Relationship Between Granulocyte JAK2 (V617F) Mutant Allele Burden and Risk of Progression to Myelofibrosis in Polycythemia Vera: a Prospective Study of 338 Patients. , 2009 .
[120] Willis X. Li. Canonical and non-canonical JAK-STAT signaling. , 2008, Trends in cell biology.
[121] K. Hoang-Xuan,et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] J. Adamson,et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. , 1976, The New England journal of medicine.
[123] N. Casadevall,et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? , 2005, Leukemia.
[124] R. Silver,et al. JAK2 Mutations are present in all cases of polycythemia vera , 2008, Leukemia.
[125] M. Loh,et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. , 2005, Blood.
[126] M. Cazzola,et al. Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia. , 2009 .
[127] Stefan N. Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.
[128] K. Takenaka,et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F , 2008, Leukemia.
[129] R. Tiedt,et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. , 2007, Blood.
[130] A. Marchetti,et al. IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.
[131] A. Kohlmann,et al. Mutations of TET2 and JAK2 but Not CBL Are Detectable in a High Portion of Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). , 2009 .
[132] N. Yoo,et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers , 2009, International journal of cancer.
[133] A. Green,et al. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. , 2010, The New England journal of medicine.
[134] A. Tefferi,et al. Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes , 2007, Leukemia.
[135] W. Vainchenker,et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. , 2008, Blood.
[136] M. McDevitt,et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] Kun-Liang Guan,et al. Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.
[138] A. Tefferi,et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status—clinical correlates in a study of 226 consecutive patients , 2010, Leukemia.
[139] A. Pardanani. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials , 2008, Leukemia.
[140] R. Levine,et al. A progenitor cell origin of myeloid malignancies , 2009, Proceedings of the National Academy of Sciences.
[141] T. Barbui,et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). , 2008, Leukemia.
[142] Christopher B. Miller,et al. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.
[143] Chunaram Choudhary,et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. , 2007, Blood.
[144] D. Gilliland,et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates , 2009, Leukemia.
[145] J. Downing,et al. Ikaros and acute leukemia , 2008, Leukemia & lymphoma.
[146] W. Dinjens,et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. , 2010, The Journal of clinical endocrinology and metabolism.
[147] P. Guglielmelli,et al. Anaemia characterises patients with myelofibrosis harbouring MplW515L/K mutation , 2007 .
[148] A. Tefferi. The history of myeloproliferative disorders: before and after Dameshek , 2008, Leukemia.
[149] A. Hall,et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. , 2008, Blood.
[150] 村松 秀城. Mutations of E3 ubiquitin ligase Cbl family members but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia , 2010 .
[151] Ashot Harutyunyan,et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms , 2009, Nature Genetics.
[152] David R. Liu,et al. Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .
[153] A. Jankowska,et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. , 2010, Blood.
[154] S. Ogawa,et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms , 2009, Nature.
[155] G. Büsche,et al. Chronic myeloproliferative diseases with concurrent BCR–ABL junction and JAK2V617F mutation , 2008, Leukemia.
[156] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[157] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[158] G. Reifenberger,et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[159] Paola Guglielmelli,et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. , 2007, Blood.
[160] P. Möller,et al. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma , 2006, Leukemia.
[161] R. Levine,et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time , 2006, British journal of haematology.
[162] A. Tefferi,et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients , 2009, Leukemia.
[163] G. Faguet,et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. , 1981, Blood.
[164] D. Gilliland,et al. Extending Jak2V617F and MplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes , 2007, Stem cells.
[165] W. Vandertop,et al. The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma , 2010, Acta Neuropathologica.
[166] Andrew Collins,et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms , 2009, Nature Genetics.
[167] D. Gilliland,et al. Concomitant neutrophil JAK2V617F mutation screening and PRV‐1 expression analysis in myeloproliferative disorders and secondary polycythaemia , 2005, British journal of haematology.
[168] R. Kralovics,et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. , 2006, Blood.
[169] D. Gilliland,et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.
[170] Tak W. Mak,et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations , 2010, The Journal of experimental medicine.
[171] J. Hess,et al. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. , 2010, Blood.
[172] A. Tefferi,et al. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.
[173] Christian Mawrin,et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.